Top-down Infliximab Study in Kids with Crohn's disease (TISKids): an international multicentre randomised controlled trial by Cozijnsen, M.A. (Maarten) et al.
Top-down Inﬂiximab Study in Kids
with Crohn’s disease (TISKids): an
international multicentre randomised
controlled trial
M A Cozijnsen,1 M van Pieterson,1 J N Samsom,2 J C Escher,1 L de Ridder,1
To cite: Cozijnsen MA,
van Pieterson M,
Samsom JN, et al. Top-down
Infliximab Study in Kids with
Crohn’s disease (TISKids): an
international multicentre
randomised controlled trial.
BMJ Open Gastro 2016;3:
e000123. doi:10.1136/
bmjgast-2016-000123
Received 11 October 2016
Revised 8 November 2016












Dr L de Ridder;
l.deridder@erasmusmc.nl
ABSTRACT
Introduction: Crohn’s disease (CD) is a chronic
inflammatory disease predominantly affecting the
gastrointestinal tract. CD usually requires lifelong
medication and is accompanied by severe
complications, such as fistulae and strictures, resulting
in surgery. Infliximab (IFX) is very effective for treating
paediatric patients with CD, but is currently only
registered for therapy refractory patients—the so-called
step-up strategy. We hypothesise that using IFX first-
line, that is, top-down, will give more mucosal healing,
fewer relapses, less complications, need for surgery
and hospitalisation.
Methods and analysis: This international
multicentre open-label randomised controlled trial
includes children, aged 3–17 years, with new-onset,
untreated CD with moderate-to-severe disease activity
(weighted Paediatric Crohn’s Disease Activity Index
(wPCDAI)>40). Eligible patients will be randomised to
top-down or step-up treatment. Top-down treatment
consists of 5 IFX infusions combined with azathioprine
(AZA). After these 5 infusions, patients will continue
AZA. Patients randomised to step-up will receive
standard induction treatment, either oral prednisolone or
exclusive enteral nutrition, combined with AZA as
maintenance treatment. The primary outcome is clinical
remission (wPCDAI<12.5) at 52 weeks without need for
additional CD-related therapy or surgery. Total follow-up
is 5 years. Secondary outcomes include clinical disease
activity, mucosal healing by endoscopy (at week 10 and
optionally week 52), faecal calprotectin, growth, quality
of life, medication use and adverse events.
Ethics and dissemination: Conducted according to
the Declaration of Helsinki and Good Clinical Practice.
Medical-ethical approval will be obtained for each site.
Trial registration number: NCT02517684;
Pre-results.
BACKGROUND
Crohn’s disease (CD) is a chronic inﬂamma-
tory disease predominantly affecting the
gastrointestinal tract. The disease pathogen-
esis is not fully known, but involves an aber-
rant immune response to the patients’
intestinal microbiota. Owing to the inﬂam-
mation, patients may present with symptoms
such as abdominal pain, diarrhoea, fatigue
and weight loss, and further investigation
may reveal increased inﬂammatory products
in the patients’ blood and faeces. The diagno-
sis is based on the patients’ history, physical
examination, endoscopic and radiological
imaging of the bowel as well as microscopic
evaluation of mucosal biopsies.1
Approximately 4 per 100 000 children
develop CD during childhood or adoles-
cence.2 Compared with adult onset CD,
patients with childhood onset may present
with more extensive and progressive disease,
and generally require more intensive treat-
ment.3 4 Paediatric CD treatment focuses on
relieving symptoms, restoring longitudinal
growth and pubertal development, and on
suppressing the inﬂammatory immune
response leading to macroscopically detect-
able repair of the mucosal surface, also
known as mucosal healing.5 Acquiring
mucosal healing is important since it predicts
a favourable disease outcome, and reduces
the need for steroids, the risk of complica-
tions, of hospitalisation and the need for
surgery.6 Current paediatric CD guidelines
instruct physicians to start treatment with
exclusive enteral nutrition (EEN) or prednis-
olone to induce disease remission, and at the
same time start with a thiopurine, such as
azathioprine (AZA), or methotrexate (MTX)
to maintain remission.5 Only patients refrac-
tory to these treatments can step up to anti-
tumour necrosis factor (anti-TNF) antibody
therapy. However, this so-called step-up treat-
ment strategy has disadvantages. Although
prednisolone and EEN both induce clinical
remission effectively (in ∼80% of patients),
prednisolone has considerable side effects,
and EEN necessitates a complete refrain from
normal food for a long period of time which
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is unpleasant and hard to comply with.5 Furthermore,
prednisolone only rarely induces mucosal healing.5 7 8
Once in clinical remission, 60–70% of patients maintain
remission during the ﬁrst year of AZA treatment.5 One
registry showed that 54% (55/102) of paediatric patients
with CD had received either an additional corticosteroid
course or had started inﬂiximab (IFX) within the ﬁrst
year after diagnosis.9 Thus, a large proportion of paediat-
ric patients require more intensive treatment in the ﬁrst
year after diagnosis. For these patients, the step-up strat-
egy delays the initiation of effective treatment and
increases the risk of CD progression and complications.
Since its introduction, IFX—the ﬁrst anti-TNF anti-
body registered for CD—has been shown to be very
effective for treating refractory paediatric patients with
CD.10 In the REACHi trial—the pivotal IFX trial in
paediatric patients with CD refractory to AZA treatment
—88% of patients responded to IFX after 10 weeks of
therapy, of whom the majority achieved and maintained
remission on IFX throughout week 54. Subsequent
research showed that IFX efﬁcacy can be improved
through individualised dose optimisation to ensure
therapeutic levels and by combination therapy with AZA
or MTX to avoid immunogenicity.11–14 Notably, IFX was
also demonstrated to be more effective the sooner it is
initiated after diagnosis. Three retrospective trials, asses-
sing the efﬁcacy of IFX, demonstrated that patients
receiving IFX ‘early’ after diagnosis (either directly after
diagnosis or <1 or 2 years afterwards) had longer remis-
sion duration and increased ﬁstula closing rates than
those receiving IFX ‘late’.15–17 Postponing IFX could
thus reduce its efﬁcacy. IFX has also been shown to
induce mucosal healing in a large proportion of
patients: In the ACCENT 1 trial in adult patients with
CD, 31% (10/32) of the patients receiving IFX mainten-
ance treatment had mucosal healing (absence of ulcers)
at week 10 and 50% (13/26) had mucosal healing at
week 54—a post-hoc analysis of week 2 IFX responders
who had mucosal ulcerations at baseline.18 Giving IFX
early as part of the top-down strategy may thus optimise
IFX efﬁcacy and offer a good chance for restoration of
the gut’s mucosa, which in turn can reduce risks of
disease relapse, hospitalisation and the need for surgery.
Evidence on the efﬁcacy of top-down treatment as
compared with step-up treatment is, however, limited.
Currently, two prospective trials compared both strat-
egies in adult patients with CD. In the ﬁrst trial,19 133
adult patients with CD were randomised to start with
either step-up treatment (steroids only) or top-down
therapy (three IFX infusions and AZA maintenance
therapy). Top-down therapy resulted in higher remission
rates (week 26: 39/65 (60%) vs 23/64 (36%); week 52:
40/65 (62%) vs 27/64 (42%)), and led more often to
mucosal healing (absence of ulcers at week 104: 19/26
(73%) vs 7/23 (30%)). In the second trial,20 77 patients
were randomised to receive either six IFX infusions and
AZA or prednisone and AZA. At week 30, top-down
treatment resulted in higher remission rates (26/38
(68%) vs 17/39 (44%)) and mucosal healing rates (17/
38 (45%) vs 7/39 (18%)).
There are no prospective randomised controlled trials
(RCTs) in paediatric patients with CD, only several retro-
spective, observational studies. The ﬁrst retrospective
study found that patients who—by either the patient’s or
physician’s choice—had started top-down treatment had
lower relapse rates at 1 year than those who had started
with step-up treatment (3/13 (23%) vs 8/13 (62%)).21
A second cohort demonstrated that IFX is more effective
in therapy naïve than refractory patients (relapse-free
rates at 3 years: 36% vs 15% (survival curve, no absolute
numbers)).15 22 23 Results from a third retrospective
cohort, using propensity scores analysis to correct for
baseline differences, showed that early IFX monotherapy
resulted in higher remission rates at 1 year than early
immunomodulator monotherapy (thiopurine or MTX)
(58/68 (85%) vs 152/248 (55%)).24 The available litera-
ture thus suggests that starting IFX therapy early is more
effective in paediatric patients with CD, but this needs to
be conﬁrmed in a prospective randomised trial. Also,
the top-down strategy by deﬁnition aims at stopping IFX
therapy and stepping down to immunomodulator mono-
therapy. This is to reduce risks associated with combin-
ation therapy,13 limit healthcare expenses while
hopefully not compromising on efﬁcacy. Whether this
approach truly offers the best risk/cost/beneﬁt balance
still needs to be tested. This study therefore aims to
compare the efﬁcacy and safety of the top-down IFX
treatment with conventional step-up treatment in paedi-
atric patients with CD with moderate-to-severe disease.
METHODS
Trial design
We designed an international multicentre open-label
RCT with two parallel treatment arms (ﬁgure 1). In add-
ition, one of these arms (step-up) contains two initial
treatment options to choose from (prednisolone and
EEN). This decision is made by the treating physician
together with the patient and/or parents. This alloca-
tion based on choice was chosen over randomised allo-
cation because of two reasons. First, this choice mimics
the current clinical practice of the step-up strategy and is
therefore a better comparator. Second, a strong aversion
to one of the step-up treatments may prevent patients
from participating in this trial.
Eligible patients willing to participate in this trial will
be randomised with concealed group allocation, result-
ing in two comparable groups. Although a double-blind
design is considered ideal for treatment comparison, an
open-label design was chosen instead, because the
former was not feasible due to the use of three
iA Randomized, multicenter, open-label study to Evaluate the safety
and efﬁcacy of Anti-TNF-a Chimeric monoclonal antibody in pediatric
subjects with moderate to severe Crohn's disease.
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treatments with different routes of administration—IFX
is given intravenously, prednisolone orally as tablets and
EEN is a liquid formula either ingested by mouth or by
nasogastric tube—which makes using placebos very
complex and costly. As a consequence of the open-label
design, our results could potentially be inﬂuenced by
performance bias and detection bias. However, since a
double-blind design is not feasible, our open-label RCT
is the optimal design for this research question.
Eligibility criteria and recruitment
Newly diagnosed patients with CD, according to the
revised Porto criteria,1 are eligible if untreated, aged 3
up to and including 17 years, with body weight above
10 kg, presenting with moderate-to-severe disease activity
(weighted Paediatric Crohn’s Disease activity Index
(wPCDAI) above 40).25 Patients are excluded in case of
a need for primary surgery, such as symptomatic bowel
stenosis or stricture, active perianal ﬁstulas, or if they
have serious comorbidity, such as a severe infection,
sepsis, opportunistic infection, positive stool culture
(Salmonella enterica/Shigella spp./Yersinia enterocolitica/
Campylobacter spp.), positive Clostridium difﬁcile toxin
assay, positive tuberculosis screening, or if they present
with a suspected or deﬁnite pregnancy.
Patients suspected of having CD and undergoing
routine diagnostic work-up are potential candidates and
screened for this trial when presenting to one of the par-
ticipating sites. After a CD diagnosis is established and eli-
gibility criteria are met, patients and/or parents/
guardians are informed about the trial and asked to con-
sider participation. After a waiting period of a minimum
of 2 days, written consent is asked for by the treating phys-
ician or researcher. Note that before the initial, diagnostic
endoscopy and study consent, preliminary consent is
sought for the collection of additional biopsies, which will
be used for search for biomarkers predictive for treat-
ment response, one of the additional study objectives.
Randomisation, blinding and treatment allocation
Eligible patients are equally (1:1 ratio) randomised by a
computer-generated list into two treatment groups, strati-
ﬁed by centre. Randomisation is incorporated in the
web-based Case Record Form (CRF) database used for
this trial (Castor Electronic Data Capture (EDC)).26
Collaborators at each site have access to this database
and can register and randomise their patients.
Treatment groups
Participants are randomised into two groups, either the
experimental ‘top-down’ group or the control group
named ‘step-up’, which is the current standard treatment
strategy.5 The top-down group will receive ﬁve IFX infu-
sions (Inﬂectra, IFX induction at weeks 0, 2 and 6, fol-
lowed by two maintenance infusions every 8 weeks, dosed
at 5 mg/kg) combined with oral AZA as maintenance
treatment (once daily, dosed 2–3 mg/kg). Step-up treat-
ment consists of standard induction treatment with
either oral prednisolone (1 mg/kg daily with a maximum
of 40 mg for 4 weeks, followed by tapering down 5 mg
per week until stop) or EEN (polymeric feeding for 6–
8 weeks after which normal diet is gradually reintroduced
within 2–3 weeks).2 Similar to the top-down group, both
prednisolone and EEN will be combined with oral AZA
as maintenance treatment (2–3 mg/kg, once daily). AZA
dosing may be altered based on thiopurine methyltrans-
ferase (TPMT) genotype, but TPMT testing is not obliga-
tory. Following its initiation, routine complete blood
counts are performed as part of routine clinical care
(weekly in ﬁrst month, monthly in second and third
months, and thereafter once every 3 months) and AZA
metabolites are measured about the time of induction
treatment cessation. In both groups, MTX may be given
instead of AZA, for instance in patients with low or absent
TPMT activity. Screening for serum positivity to Varicella
zoster virus—as well as Epstein-barr virus and hepatitis B—is
part of routine clinical care, and if vaccination is required
and if time allows, treatment initiation will be postponed.
The top-down and step-up groups differ in the type of
induction treatment that is started after diagnosis, but may
switch to similar treatments during follow-up. Treating phy-
sicians are allowed to change treatment or increase dosing
during follow-up when clinically indicated, for instance in
case of drug inefﬁcacy (non-response or loss of response)
or intolerance. IFX may thus also be given to a step-up
patient, but only as second-line treatment. Note that the
step-up group may thus include patients stepping up to
IFX early after diagnosis, which, as explained in the intro-
duction, was associated with better efﬁcacy in retrospective
trials than starting IFX late. Overall, this study thus
Figure 1 Study design. EEN,
exclusive enteral nutrition; IFX,
infliximab; opt, optional; wPCDAI,
weighted Paediatric Crohn’s
Disease Activity Index.25
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compares two treatment strategies and not two different
drugs, like in regular drug trials.
Study end points
Comparative efficacy and safety
In total, patients will be followed for 5 years from ran-
domisation (ﬁgure 1). The primary end point is clinical
remission at week 52 (deﬁned as a wPCDAI score<12.5)
without need for additional CD-related therapy or
surgery, that is, additional to the treatment scheme
described in the previous section (table 1).
Secondary end points include assessment of endo-
scopic disease activity, growth, quality of life and medica-
tion use. Endoscopic disease activity is an important
outcome in this trial due to the expected difference
between the two treatment strategies. To assess endo-
scopic disease activity, an endoscopic examination is
scheduled at week 10, and another offered at week 52.
The week 52 endoscopy is performed on a voluntary
basis, as most patients may not beneﬁt from this assess-
ment while it does pose risk and discomfort. Endoscopic
disease activity is also indirectly assessed via measuring
the faecal marker calprotectin. To address longitudinal
growth during follow-up, height and body mass index
Z-scores will be calculated at baseline and during
follow-up for all patients with use of age-speciﬁc and
gender-speciﬁc anthropometric reference values (prefer-
ably country-speciﬁc, otherwise global reference values).
Additionally, bone age will be measured with hand X-ray,
and pubertal development will be assessed. Safety end
points include the rate of adverse events and complica-
tions during follow-up.
Besides comparing the two treatment strategies top-
down and step-up with each other, we planned two suba-
nalyses. First, we aim to compare both the efﬁcacy and
safety of the two step-up treatment options, and second,
to assess the correlation between clinical and endoscopic
disease activity measures.
Healthcare costs, response prediction, and evaluation of the
kinetic and dynamic properties of IFX
Three additional objectives are set. First, an additional
objective is to compare the healthcare-related cost of
both treatment strategies. This is an important outcome,
because of the large difference in costs between bio-
logical and non-biological drugs. The recent introduc-
tion of an IFX biosimilar to the market has strongly
reduced the costs of IFX therapy, while the costs of
top-down therapy may be further reduced compared
with step-up therapy by its hypothesised higher efﬁcacy,
which may reduce medication use, hospitalisation and
Table 1 Study end points
Time (weeks)
Primary end point
Remission* without a need for additional CD-related therapy or surgery 52
Secondary efficacy end points
Remission* and response† 10, 52
Endoscopic disease activity (presence of ulcers, SES-CD) 10, optionally 52
Faecal calprotectin 10, 52
Height and BMI Z-scores, bone age and pubertal development 52
Quality of life (IMPACT-III) 14, 52
Cumulative therapy use and therapy failure 52
Secondary safety end points
Adverse events and complications 52
Long-term end points
Remission* without a need for additional CD-related therapy or surgery 104, 156, 208, 260
Remission* and response† 104, 156, 208, 260
Faecal calprotectin 104, 156, 208, 260
Number of flares 104, 156, 208, 260
Quality of life (IMPACT-III) 260
Cumulative therapy use and therapy failure 260
Adverse events and complications 260
Subanalyses
Comparing efficacy and safety of prednisolone plus AZA with EEN plus AZA
Correlations between wPCDAI, faecal calprotectin and endoscopic disease severity (SES-CD)
Additional objectives
Comparing the cost-effectiveness of top-down with that of step-up
Identifying predictive biomarkers for treatment response
Assessing the pharmacokinetic and pharmacodynamic properties of IFX in children
*Remission: wPCDAI<12.5.
†Response: wPCDAI decrease >17.5.
AZA, azathioprine; BMI, body mass index; EEN, exclusive enteral nutrition; IFX, infliximab; IMPACT-III;27 28 SES-CD, simplified endoscopic
activity score for Crohn’s disease;29 wPCDAI, weighted Paediatric Crohn’s Disease Activity Index.25
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surgery.6 We therefore hypothesise that after 5 years of
follow-up healthcare-related costs of top-down therapy
will be comparable to those of step-up therapy.
We will also look for biological markers that may
predict treatment response. Additional biopsies and
blood samples are collected from patients to measure
RNA and protein expression, both before the start of
treatment and during follow-up (additional biopsies are
taken in pairs from affected and unaffected mucosal
tissue in the ileum and colon with a maximum of eight
biopsies). This may help unravel the underlying
mechanisms of treatment response of both strategies
and preferentially lead to markers predictive of treat-
ment response. The ability to predict treatment response
prior to its initiation would allow for tailored treatment,
aimed at maximal effect and safety hereby decreasing
healthcare cost.
Finally, the pharmacokinetic and pharmacodynamic
properties of IFX in children will be assessed during
follow-up. Currently, only a few controlled trials have
assessed these properties of IFX in children and by gath-
ering more, high-quality data, we expect to further opti-
mise IFX dosing in children. On the basis of clinical
experience, we hypothesise that ﬁxed IFX dosing of 5
mg/kg will result in lower IFX trough levels in younger
patients and as a consequence in lower drug efﬁcacy.
Sample size calculation
Our sample size calculation was based on the week 52
remission ratios in three studies, two retrospective trials
in paediatric patients with CD and one prospective RCT
among adult patients with CD. The ﬁrst retrospective
trial compared top-down IFX use with conventional
step-up IFX use in paediatric CD and found a remission
difference at week 52 of 38% (15/18 (83%) vs 5/11
(45%)).23 The second trial compared early IFX use with
early immunomodulator use and found a remission dif-
ference of 24% (58/68 (85%) vs 152/248 (61%)).24
The only prospective RCT, comparing top-down with
step-up treatment in adult patients with CD, reported a
remission difference of 19% at week 52 (40/65 (61.5%)
vs 27/64 (42.2%)).19 On the basis of these data, we cal-
culated a need for 100 inclusions (50 patients in each
arm, considering a drop-out rate of 2%) to ﬁnd a 25%
difference in clinical remission at week 52 with a power
of 80% (two-sided α 0.05). A low drop-out rate was con-
sidered appropriate, because there are only a few
reasons for dropping out: only if the patient wishes to,
or if after randomisation the assigned treatment is not
started.
Data collection and monitoring
Data are collected in Castor EDC,26 a web-based CRF
database enabling the central study coordinators to follow
and check the CRF input of each of the collaborating
centres online. Additionally, a certiﬁed monitor will visit
each site every year. A Data Safety Monitoring Board was
not appointed, as the risks of adverse events associated
with this study are considered low, because only approved
therapies are used and treatment is not blinded.
Statistic methods
Subject baseline and demographic data as well as base-
line disease characteristics data will be summarised by
treatment group. Parametric variables will be described
by their mean and SD, and compared with use of the
Student’s t-test, and non-parametric variables will be
described by their median and IQR and compared
using the Mann-Whitney U test. Categorical variables
will be summarised using counts and percentages, and
compared using the χ2 test, or the Cox proportional
hazard test in case of time-dependent categorical vari-
ables. Correlations will be assessed using either the
Pearson correlation coefﬁcient (parametric) or the
Spearman’s rank correlation coefﬁcient (non-
parametric). Analyses will be performed on an
intention-to-treat basis. All statistical testing will be two-
sided and signiﬁcant at the 0.05 level. Missing data will
be reported and left out of the analyses.
DISCUSSION
Top-Down Inﬂiximab Study in Kids with Crohn’s disease
(TISKids) is a unique study speciﬁcally designed to
compare two treatment strategies. Two comparable
groups are generated through randomisation so that
each group only differs by the initial induction treat-
ment started. During a 5-year follow-up period, the
effects of these two strategies will be compared. Both
major patient-related outcomes as well as other import-
ant healthcare-related outcomes will be addressed
aiming to obtain as much information as possible con-
cerning the beneﬁts, risks and costs of both strategies.
In recent years, and because of increasing literature
supporting early IFX use, IFX is being prescribed
increasingly sooner after diagnosis. The guidelines for
paediatric CD treatment were changed in their recom-
mendations on this topic. They now advocate ﬁrst-line
IFX use for children with active perianal ﬁstulising
disease and state that ﬁrst-line IFX may also be consid-
ered for patients with high risk of poor outcome.5
However, the data supporting this recommendation is
not conclusive. The beneﬁts and risks of this new strat-
egy are not well studied, nor compared with those of the
conventional step-up strategy. The comparative risks and
costs of top-down treatment are not especially well
known. This study will thus offer solid answers to these
important and urgent clinical questions.
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